33 Participants Needed

Telmisartan for Ovarian Cancer

KF
Overseen ByKayla Fay
Age: 18+
Sex: Female
Trial Phase: Phase 2
Sponsor: Tyler J Curiel
Must be taking: Standard chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications, but you cannot use ACE inhibitors like ramapril or have taken rituximab or amifostine within 30 days before starting telmisartan. It's best to discuss your current medications with the trial team.

How does the drug Telmisartan differ from other treatments for ovarian cancer?

Telmisartan is unique for ovarian cancer treatment as it is primarily an angiotensin receptor blocker used for high blood pressure, and its repurposing aims to overcome chemoresistance, offering a novel approach compared to traditional chemotherapy options.12345

Who Is on the Research Team?

IW

Ivy Wilkinson-Ryan, MD

Principal Investigator

Dartmouth Health

Are You a Good Fit for This Trial?

This trial is for women over 18 with high-grade serous ovarian cancer that's resistant to platinum-based chemotherapy. They must have a life expectancy of at least 2 months, be willing to use contraception, and have stable blood pressure. Excluded are pregnant or lactating women, those with significant heart conditions or infections, and anyone on certain medications like ACE inhibitors.

Inclusion Criteria

I am eligible for standard chemotherapy for ovarian cancer.
FCBP must have a negative serum pregnancy test at screening
My ovarian cancer is a high-grade serous type.
See 9 more

Exclusion Criteria

Pregnant or lactating
Incarcerated or homeless
If known to be HIV-infected, have undetectable HIV viral load by any accepted standard of care HIV detection method
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral telmisartan in combination with standard of care chemotherapy regimens

48 months
Regular visits for chemotherapy administration and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months
Periodic visits for monitoring progression-free survival and treatment tolerability

What Are the Treatments Tested in This Trial?

Interventions

  • Telmisartan
Trial Overview The study tests if adding Telmisartan to standard chemotherapy improves progression-free survival in patients compared to past data. Participants will receive Telmisartan alongside their regular chemo regimen and will be monitored for changes in the growth of their cancer.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Telmisartan with Standard of Care TreatmentExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Tyler J Curiel

Lead Sponsor

Trials
2
Recruited
70+

Dartmouth-Hitchcock Medical Center

Collaborator

Trials
548
Recruited
2,545,000+

Published Research Related to This Trial

Olaparib, a PARP inhibitor, showed a 36% objective response rate in women with relapsed ovarian cancer and a germline BRCA1/2 mutation, even after they had undergone multiple lines of chemotherapy, indicating its efficacy in this challenging patient population.
The median duration of response to olaparib was 7.4 months, and the safety profile was consistent across patients who had received three or more lines of prior chemotherapy, with similar rates of serious adverse events.
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.Matulonis, UA., Penson, RT., Domchek, SM., et al.[2022]

Citations

Angiotensin-converting enzyme inhibitors for ovarian cancer? - a new adjuvant option or a silent trap. [2023]
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. [2021]
Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12. [2022]
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. [2022]
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security